BATESVILLE, Ind., June 9, 2020 /PRNewswire/ -- Hillenbrand,
Inc. (NYSE: HI) has announced the commencement and pricing of its
public offering of $400 million
aggregate principal amount of 5.7500% senior unsecured notes due
2025 (the "Notes"). The aggregate principal amount of the Notes to
be issued in the offering was increased to $400 million from the previously announced
$300 million. The offering is expected to close on or
about June 16, 2020, subject to
customary closing conditions.
Hillenbrand intends to use the net proceeds from this offering
for general corporate purposes, including debt repayment, such as
the repayment of the entire $150
million aggregate principal amount outstanding of the
5.5000% senior notes due 2020 at maturity.
HSBC Securities (USA)
Inc., Citizens Capital Markets, Inc., J.P. Morgan Securities
LLC and PNC Capital Markets LLC are the bookrunners for the
offering. The offering of the Notes is being made only by means of
a prospectus. A copy of the prospectus may be obtained by calling
HSBC Securities (USA) Inc. at
866-811-8049, Citizens Capital Markets, Inc. at
617-960-1898, J.P. Morgan Securities LLC at 212-834-4533 or
PNC Capital Markets LLC at 855-881-0697.
This press release is not an offer to sell or a solicitation of
an offer to buy any security and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offering,
solicitation or sale would be unlawful.
About Hillenbrand
Hillenbrand is a global
diversified industrial company with businesses that serve a wide
variety of industries around the world. We pursue profitable growth
and robust cash generation to drive increased value for our
shareholders. Hillenbrand's portfolio includes industrial
businesses such as Coperion, Milacron Injection Molding &
Extrusion, and Mold-Masters, in addition to Batesville, a recognized leader in the death
care industry in North America.
Hillenbrand is publicly traded on the NYSE under "HI."
Forward-Looking Statements
Throughout this release, we
make a number of "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. As the words
imply, these are statements about future plans, objectives,
beliefs, and expectations that might or might not happen in the
future, as contrasted with historical information. Forward-looking
statements are based on assumptions that we believe are reasonable,
but by their very nature are subject to a wide range of risks. If
our assumptions prove inaccurate or unknown risks and uncertainties
materialize, actual results could vary materially from
Hillenbrand's (the "Company") expectations and projections.
Words that could indicate that we are making forward-looking
statements include the following:
intend
|
believe
|
plan
|
expect
|
may
|
goal
|
would
|
project
|
become
|
pursue
|
estimate
|
will
|
forecast
|
continue
|
could
|
anticipate
|
target
|
impact
|
promise
|
improve
|
progress
|
potential
|
should
|
|
This is not an exhaustive list, but is intended to give you an
idea of how we try to identify forward-looking statements. The
absence of any of these words, however, does not mean that the
statement is not forward-looking.
Here is the key point: Forward-looking statements are
not guarantees of future performance, and our actual results could
differ materially from those set forth in any forward-looking
statements. Any number of factors, many of which are beyond our
control, could cause our performance to differ significantly from
what is described in the forward-looking statements. These factors
include, but are not limited to: the impact of contagious diseases
such as the COVID-19 pandemic and the societal, governmental, and
individual responses thereto, including supply chain disruption,
loss of contracts and/or customers, erosion of some customers'
credit quality, closure or temporary interruption of the Company's
or suppliers' manufacturing facilities, travel, shipping and
logistical disruptions, loss of human capital or personnel, and
general economic calamities that could result in an extended
shutdown or reduction of our operations, substantially reduced
sales volumes, or supply constraints; the outcome of any legal
proceedings that may be instituted against the Company, or any
companies we may acquire; risks that the integration of Milacron or
any other integration, acquisition, or disposition activity
disrupts current operations or poses potential difficulties in
employee retention or otherwise affects financial or operating
results; the ability to recognize the benefits of the acquisition
of Milacron or any other acquisition or disposition, including
potential synergies and cost savings or the failure of the Company
or any acquired company to achieve its plans and objectives
generally; global market and economic conditions, including those
related to the credit markets; volatility of our investment
portfolio; adverse foreign currency fluctuations; involvement in
claims, lawsuits and governmental proceedings related to
operations; our reliance upon employees, agents, and business
partners to comply with laws in many countries and jurisdictions;
labor disruptions; the impact of the additional indebtedness that
the Company has incurred in connection with the acquisition of
Milacron and the ability of the Company to comply with financial or
other covenants in its debt agreements or meet its de-leveraging
goals; the dependence of our business units on relationships with
several large providers; increased costs or unavailability of raw
materials or certain outsourced services; continued fluctuations in
mortality rates and increased cremations; competition in the
industries in which we operate, including from nontraditional
sources in the death care industry; our level of international
sales and operations; cyclical demand for industrial capital goods;
impacts of decreases in demand or changes in technological
advances, laws, or regulation on the revenues that we derive from
the plastics industry; certain tax-related matters; and changes to
legislation, regulation, treaties or government policy, including
any resulting from the current political environment. For a more
in-depth discussion of these and other factors that could cause
actual results to differ from those contained in forward-looking
statements, see the discussions under the heading "Risk Factors" in
Part I, Item 1A of Hillenbrand's Form 10-K for the year ended
September 30, 2019, filed with the
Securities and Exchange Commission on November 13, 2019, and in Part II, Item 1A of
Hillenbrand's Form 10-Q for the quarter ended March 31, 2020, filed with the Securities and
Exchange Commission on May 6, 2020;
and in Hillenbrand's other filings with the U.S. Securities and
Exchange Commission, including on Forms 8-K and S-3. The
forward-looking information in this release speaks only as of the
date covered by this report, and the Company assumes no obligation
to update or revise any forward-looking information.
CONTACTS
Corporate Communications for
Hillenbrand
Paul Whitmore,
Manager of Corporate Communications
Phone: 812-931-5412
E-mail: paul.whitmore@hillenbrand.com
Investor Relations for Hillenbrand
Rich Dudley, Senior Director, Investor
Relations
Phone: 812-931-5001
E-mail: rich.dudley@hillenbrand.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hillenbrand-announces-commencement-and-pricing-of-upsized-400-million-senior-notes-offering-301073191.html
SOURCE Hillenbrand, Inc.